Sagimet Biosciences (STU:0O2) Change In Working Capital: €-2.92 Mil (TTM As of Mar. 2026)

What is Sagimet Biosciences Change In Working Capital?

Sagimet Biosciences STU:0O2 +1.66% 10 Change In Working Capital is €-2.92 Mil as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Sagimet Biosciences's change in working capital for the quarter that ended in Mar. 2026 was €0.26 Mil.

Sagimet Biosciences's change in working capital for the fiscal year that ended in Dec. 2025 was €-0.90 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Sagimet Biosciences Change In Working Capital Related Terms

Sagimet Biosciences Change In Working Capital Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences Change In Working Capital Chart

Sagimet Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Change In Working Capital

Get a 7-Day Free Trial

-0.05

3.98

-0.90

-1.00

-0.90

Sagimet Biosciences Quarterly Data
	Dec20	Mar21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Change In Working Capital	Get a 7-Day Free Trial															2.46	-0.11	0.60	-3.67	0.26

10GF Score

Sagimet Biosciences Inc STU:0O2

Change In Working Capital is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Sagimet Biosciences Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.92 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Frequently Asked Questions Learn more about Change In Working Capital →

What does a Change In Working Capital of €-2.92 Mil mean?

Sagimet Biosciences (STU:0O2) has a Change In Working Capital of €-2.92 Mil as of Mar. 2026. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for Sagimet Biosciences.

Is Sagimet Biosciences' Change In Working Capital too high?

Sagimet Biosciences' current Change In Working Capital is €-2.92 Mil. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.

How does Sagimet Biosciences' Change In Working Capital compare to EDIT and AUTL?

Sagimet Biosciences' Change In Working Capital of €-2.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Change In Working Capital for a Biotechnology company?

A good Change In Working Capital depends on the Biotechnology industry context. However, Change In Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Change In Working Capital mean?

A high Change In Working Capital can signal that a stock is expensive relative to its fundamentals. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for Sagimet Biosciences. Sagimet Biosciences's current Change In Working Capital is €-2.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Sagimet Biosciences stock overvalued right now?

Sagimet Biosciences (STU:0O2) has a current Change In Working Capital of €-2.92 Mil. The current Change In Working Capital is €-2.92 Mil. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Change In Working Capital calculated?

Change In Working Capital is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Change In Working Capital is €-2.92 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sagimet Biosciences Business Description

Industry Healthcare Biotechnology

Comparable Companies EDIT AUTL FBRX BNTC INDP IPSC PBYI ENTA ARTV OVID VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges SGMT:USA

Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402

Website https://www.sagimet.com

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

10GF Score

Get the complete analysis for STU:0O2

Change In Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.14

Price

View STU:0O2 Analysis

See Change In Working Capital data for all stocks →